-
公开(公告)号：US10758557B2
公开(公告)日：2020-09-01
申请号：US16440659
申请日：2019-06-13
IPC分类号： A61K31/7076 , A61K31/708 , C07H19/04 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , A61K31/7068 , A61K31/7072 , A61K45/06 , A61K31/7056 , A61K38/21 , G03C1/005
摘要： A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
-
公开(公告)号：US20190290670A1
公开(公告)日：2019-09-26
申请号：US16440659
申请日：2019-06-13
IPC分类号： A61K31/708 , A61K38/21 , A61K31/7056 , C07H19/10 , C07H19/20 , C07H19/16 , A61K31/7068 , C07H19/06 , C07H19/04 , A61K45/06 , A61K31/7076 , A61K31/7072
摘要： A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
-
公开(公告)号：US20180235993A1
公开(公告)日：2018-08-23
申请号：US15952117
申请日：2018-04-12
IPC分类号： A61K31/7072 , C07H19/20 , A61K38/21 , A61K31/7052 , A61K31/7056 , C07H19/16 , A61K31/7076 , C07H19/23 , C07H19/06 , C07H19/073 , C07H19/10 , A61K31/7064
CPC分类号： A61K31/7072 , A61K31/7052 , A61K31/7056 , A61K31/7064 , A61K31/7076 , A61K38/21 , C07H19/06 , C07H19/073 , C07H19/10 , C07H19/16 , C07H19/20 , C07H19/23 , Y02A50/385 , Y02A50/387 , Y02A50/389
摘要： A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
-
公开(公告)号：US10525072B2
公开(公告)日：2020-01-07
申请号：US14972009
申请日：2015-12-16
IPC分类号： C12Q1/70 , A61K31/7072 , A61K31/7052 , A61K38/21 , A61K45/06 , C07H19/06 , C07H19/16 , C07K14/005 , C12Q1/04 , C12Q1/18
摘要： The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.
-
公开(公告)号：US10363265B2
公开(公告)日：2019-07-30
申请号：US13730669
申请日：2012-12-28
IPC分类号： A61K31/7072 , A61K31/7068 , A61K31/708 , C07H19/04 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , A61K31/7076 , A61K45/06 , A61K31/7056 , A61K38/21 , G03C1/005
摘要： A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
-
公开(公告)号：US20210024565A1
公开(公告)日：2021-01-28
申请号：US17061409
申请日：2020-10-01
申请人： Idenix Pharmaceuticals LLC , Universita degli Studi di Cagliari , Centre National De La Recherche Scientifique , Universite de Montpellier
IPC分类号： C07H19/16 , A61K47/60 , A61K31/675 , A61K31/7072 , A61K31/7076 , A61K38/21 , A61K45/06 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/22 , A61K31/7068 , A61K31/708 , C07H19/056 , C07H19/06 , A61K31/7056 , A61K9/20 , A61K9/48
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
公开(公告)号：US20180237467A1
公开(公告)日：2018-08-23
申请号：US15890990
申请日：2018-02-07
申请人： Idenix Pharmaceuticals LLC , Universita degli Studi di Cagliari , Centre National De La Recherche Scientifique , Universite de Montpellier
IPC分类号： C07H19/16 , A61K31/7056 , A61K45/06 , C07H19/06 , C07H19/056 , A61K38/21 , A61K31/708 , A61K31/7068 , A61K47/60 , A61K9/48 , A61K9/20 , A61K31/675 , A61K31/7072 , A61K31/7076 , C07H19/22 , C07H19/048 , C07H19/04 , C07H19/00
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
公开(公告)号：US20130149283A1
公开(公告)日：2013-06-13
申请号：US13730669
申请日：2012-12-28
IPC分类号： A61K31/708 , A61K31/7076 , A61K45/06 , A61K31/7072 , A61K31/7068 , C07H19/16 , C07H19/06
CPC分类号： A61K31/708 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K38/21 , A61K45/06 , C07H19/04 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , G03C1/0051
摘要： A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
-
公开(公告)号：US09968628B2
公开(公告)日：2018-05-15
申请号：US13675937
申请日：2012-11-13
IPC分类号： A61K31/7052 , A61K31/7072 , A61K31/7076 , C07H19/06 , C07H19/10 , C07H19/16 , C07H19/20 , C07H19/073 , C07H19/23 , A61K31/7056 , A61K31/7064 , A61K38/21
CPC分类号： A61K31/7072 , A61K31/7052 , A61K31/7056 , A61K31/7064 , A61K31/7076 , A61K38/21 , C07H19/06 , C07H19/073 , C07H19/10 , C07H19/16 , C07H19/20 , C07H19/23 , Y02A50/385 , Y02A50/387 , Y02A50/389
摘要： A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
-
10.发明申请MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS 审中-公开用于治疗感冒的改良的2'和3'-核苷酸产物公开(公告)号：US20130330297A1
公开(公告)日：2013-12-12
申请号：US13958463
申请日：2013-08-02
申请人： Idenix Pharmaceuticals, Inc. , L'Universite Montpellier II (UMII) , Centre National De La Recherche Scientifique (CNRS) , Universita degli Studi di Cagliari
IPC分类号： A61K38/21 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K31/7076
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
摘要翻译： 描述了1'，2'，3'或4'-支链核苷的2'和/或3'前药及其药学上可接受的盐和衍生物。 这些前药可用于预防和治疗黄病毒科感染，包括HCV感染和其他相关病症。 描述本发明前药的化合物和组合物。 还提供了包括施用有效量的本发明前药或其药学上可接受的盐或衍生物的方法和用途。 这些药物可以任选地与另外的抗病毒剂组合或改变来施用，以预防或治疗黄病毒科感染和其他相关病症。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.026 秒)
